BioPharma Resources

Drug Trial Radar · NCT07889284

Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout

A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Multi-centre Study to Evaluate the Efficacy, Safety, and Tolerability of Combined Metabolic Activator (CMA2) Supplementation in Individuals With Hyperuricemia Associated With Gout

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 336 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

336

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Feb 2027

Study completion Feb 2027

Sponsor

Lead sponsor
ScandiBio Therapeutics ABIndustry
Sponsor type
Industry
First posted
Oct 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Supportive care
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This will be a randomised, double-blind, placebo-controlled, multi-centre study with the aim to establish metabolic improvements in individuals diagnosed with hyperuricemia associated with gout by treatment with CMA2 including N-acetyl-L-cysteine (NAC), L-carnitine-L-tartrate (LCAT), nicotinamide (niacinamide), and L-serine for 4 weeks.

Conditions

  • Gout Disease

Interventions

  • Combined metabolic activatorsDrug

    A total of 20g of CMA2 with strawberry aroma and colouring agent will be given. The IMP will be provided as a soluble powder packed as individual dosages in identical sachets. The powder should be dissolved in 200 ml preferably cold water before use. The powder can also be used on yoghurt or other food. The subjects will take two daily oral doses of the IMP, one dose just after breakfast and one dose just after dinner. Subjects who cannot tolerate (e.g., diarrhoea) taking full dose will be withdrawn from the study.

  • Collagen and maltodextrinOther

    As placebo, a total of 20g of compound primarily containing collagen and maltodextrin will be administered. Placebo contains strawberry aroma flavouring and colouring agent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the effect of 4-weeks administration of CMA2 treatment on serum uric acid levels in participants diagnosed with hyperuricemia associated with gout, as compared with placebo.Time frame: 4 weeks

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Ankara Bilkent City Hospital

    Ankara, Turkey (Türkiye)

  • Alanya Training and Research Hospital

    Antalya, Turkey (Türkiye)

  • Atatürk University Research Hospital

    Erzurum, Turkey (Türkiye)

  • Erzurum City Hospital

    Erzurum, Turkey (Türkiye)

  • Eskişehir Osmangazi University Faculty of Medicine Hospital

    Eskişehir, Turkey (Türkiye)

  • Göztepe Prof. Dr. Süleyman Yalçın City Hospital

    Istanbul, Turkey (Türkiye)

  • Istanbul University-Cerrahpaşa Faculty of Medicine Hospital

    Istanbul, Turkey (Türkiye)

  • Kanuni Sultan Süleyman Training and Research Hospital

    Istanbul, Turkey (Türkiye)

  • Kartal Dr. Lütfi Kırdar City Hospital

    Istanbul, Turkey (Türkiye)

  • Koç University Hospital

    Istanbul, Turkey (Türkiye)

  • Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital

    Istanbul, Turkey (Türkiye)

  • Sultan 2nd Abdülhamid Han Training and Research Hospital

    Istanbul, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.